1. Home
  2. RELY vs IBRX Comparison

RELY vs IBRX Comparison

Compare RELY & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Remitly Global Inc.

RELY

Remitly Global Inc.

HOLD

Current Price

$14.59

Market Cap

2.6B

Sector

Technology

ML Signal

HOLD

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$2.29

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RELY
IBRX
Founded
2011
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.3B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
RELY
IBRX
Price
$14.59
$2.29
Analyst Decision
Buy
Strong Buy
Analyst Count
10
7
Target Price
$26.00
$9.71
AVG Volume (30 Days)
3.3M
14.5M
Earning Date
11-05-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.09
N/A
Revenue
$1,544,865,000.00
$82,555,000.00
Revenue This Year
$30.78
$667.18
Revenue Next Year
$18.39
$88.32
P/E Ratio
$155.13
N/A
Revenue Growth
31.27
1025.95
52 Week Low
$12.08
$1.83
52 Week High
$27.32
$4.27

Technical Indicators

Market Signals
Indicator
RELY
IBRX
Relative Strength Index (RSI) 56.35 52.78
Support Level $14.43 $2.00
Resistance Level $14.78 $2.50
Average True Range (ATR) 0.51 0.14
MACD 0.15 -0.00
Stochastic Oscillator 58.78 53.00

Price Performance

Historical Comparison
RELY
IBRX

About RELY Remitly Global Inc.

Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Share on Social Networks: